ITEMS IN AFP WITH KEYWORD:
Chronic Obstructive Pulmonary Disease
Aug 1, 2008 Issue
ACP Guideline Recommends Diagnosis and Management Strategies for COPD [Practice Guidelines]
The American College of Physicians (ACP) has released a guideline providing recommendations on the diagnosis and treatment of chronic obstructive pulmonary disease (COPD).
Chronic obstructive pulmonary disease affects more than 26 million adults in the United States. Family physicians provide care for most of these patients. Cigarette smoking is the leading risk factor for chronic obstructive pulmonary disease, although other risk factors, including occupational and e...
Jun 1, 2008 Issue
Use of Inhaled Corticosteroids to Treat Stable COPD [Cochrane for Clinicians]
Although the use of inhaled corticosteroids for COPD will not reduce mortality or affect long-term disease progression, inhaled corticosteroids can be useful for reducing COPD exacerbations and slowing declines in quality of life.
Is fluticasone plus salmeterol better than fluticasone or salmeterol alone for treating patients with COPD? Anticholinergics are the bronchodilators of choice. Neither fluticasone nor the combination of fluticasone and salmeterol were no better than placebo at preventing mortality.
Chronic obstructive pulmonary disease (COPD) is a common problem among patients presenting to primary care. This condition has multiple individual and combined treatment regimens. The goals of treatment are to improve quality of life, exercise tolerance, sleep quality, and survival; and to reduce dy...
In 20 studies of cardioselective beta blockers in patients with COPD, participants had no adverse pulmonary or respiratory effects. Because of their salutary cardiovascular effects, cardioselective beta blockers should not be withheld from patients with COPD.
There is consistent evidence from a small number of studies that antibiotics significantly reduce mortality (number needed to treat [NNT] = 8) and treatment failure (NNT = 3) in more severely ill patients with COPD who are hospitalized because of an exacerbation. Two smaller studies found no benefit...
Chronic obstructive pulmonary disease is characterized by the gradual progression of irreversible airflow obstruction and increased inflammation in the airways and lung parenchyma that is generally distinguishable from the inflammation caused by asthma. Most chronic obstructive pulmonary disease is ...
In patients with moderate or severe COPD, tiotropium reduces exacerbations, hospitalizations, and symptom scores and improves health-related quality of life compared with placebo and ipratropium (Atrovent). However, more study is needed to determine tiotropium’s role in the treatment of COPD compared with long-acting beta agonists.
Aug 1, 2005 Issue
Systemic Corticosteroids for Acute Exacerbations of COPD [Cochrane for Clinicians]
Systemic corticosteroids improve symptoms of acute COPD exacerbations at three days and reduce the likelihood of treatment failure. There is no evidence that they reduce mortality or prevent recurrence at 30 days, but the existing studies may be too small to detect such a benefit. Adverse effects are common but generally are not serious.